Preventing AML Relapse with Cell Engineering

Hi friends 👋🏼,

The Cure was launched on March 12, 2023, and hit 400 subscribers this week! 🥳 If you enjoy it, please share us with your colleagues, friends, and communities.

Here’s what we’ll break down this week:

• Preventing AML Relapse with Cell Engineering ^{READER REQUEST}

• First Patient Dosed in Parkinson’s Stem Cell Trial

• Targeting Integrins in Primary Sclerosing Cholangitis ^{READER REQUEST}

• Duchenne Muscular Dystrophy Trial Begins Recruitment ^{READER REQUEST}

 🩸Preventing AML Relapse with Cell Engineering

Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow, causing an overproduction of abnormal blood cells that can lead to infection, anemia, bleeding, and, eventually, death.

1/ Current treatment of AML usually consists of chemotherapy followed by a hematopoietic stem cell transplant (HSCT) to “clean out” cancerous cells from the bone marrow.

2/ After stem cell transplantation, patients can no longer receive targeted cancer therapies since those same therapies would be toxic to the fragile and newly transplanted cells. As a result, around 40% of patients who receive a stem cell transplant relapse, and less than 20% survive another two years.

3/ Vor Bio is developing a novel approach to help stop this relapse by engineering hematopoietic stem cells in a way that allows for follow-up targeted cancer therapies.

How Vor Bio’s cell therapy works 👇🏼

Subscribe to The Cure to read the rest.